The total number of records retrieved from this search are 36. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_606	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineKey Laboratory of Zoonosis, Jilin University	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_609	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineKey Laboratory of Zoonosis, Jilin University	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_612	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineKey Laboratory of Zoonosis, Jilin University	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result18% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_615	Virus nameAdenovirus	Virus strainCRAd-CCL21-IL15	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertion mutant for CCL21 and IL15 genes with TERTp to target the TERT-positive cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeIL-15	Source of cell lineKey Laboratory of Zoonosis, Jilin University	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1.0E+5 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result10% cancer cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27380620
IDOV_898	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result2% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_899	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result20% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_900	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result50% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_901	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result20% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_902	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result40% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_903	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result80% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_904	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result60% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_905	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result80% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_906	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.01 pfu/cell	In-vitro result90% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_907	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result20% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_908	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result30% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_909	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result50% cancer cell killing after 24 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_910	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result50% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_911	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result60% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_912	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result100% cancer cell killing after 48 hour	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_913	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result60% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_914	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result80% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_915	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineProstate cancer cell line	Cell linePC-3M-Pro4	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayTrypan blue staining	In-vitro virus concentration0.1 pfu/cell	In-vitro result100% cancer cell killing after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_3724	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M-Luc	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration0.1 MOI	In-vitro result50% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_3731	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M-Luc	Concentration of cell lineNA	In-vitro toxicityNA	AssayAbsorbance measurements	In-vitro virus concentration10 MOI	In-vitro result18% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryVirus induce apoptosis in cancer cell	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636
IDOV_4909	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4910	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4911	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4912	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4913	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4914	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4915	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4916	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result15% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4917	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4918	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result40% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4919	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result15% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859
IDOV_4920	Virus nameAdenovirus	Virus strainwild type	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of IL21 and CCL21gene in virus genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-21 and CCL21 gene	Source of cell lineJilin University china	Origin of cell lineHuman prostate cancer cell line	Cell linePC-3M	Concentration of cell line1 million cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration50 MOI	In-vitro result15% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectActivate proloferation of B-cell and Naive T-cell	Clinical trialNA	PMID27157859